在利妥昔单抗时代的原发性结外弥漫性大 B 细胞淋巴瘤：单中心回顾性分析。
Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis.
机构信息
Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
出版信息
Hematology. 2022 Dec;27(1):757-764. doi: 10.1080/16078454.2022.2091197.
OBJECTIVES
To analyse the clinical characteristics and therapeutic response of Chinese patients with primary extranodal diffuse large B-cell lymphoma DLBCL (PE-DLBCL).
METHODS
We analysed the clinical features and outcomes of 197 patients who were newly diagnosed with PE-DLBCL between January 2015 and December 2020.
RESULTS
The gastrointestinal tract showed the highest rate of involvement (34%), followed by the central nervous system (CNS) and intraocular system (31.5%). The 3-year overall survival (OS) rate was 81% for the entire group and 79% for those with CNS and vitreoretinal involvement. Ann Arbour stage, lactate dehydrogenase level, International Prognostic Index > 2, and complete remission (CR) were significantly related to the survival of patients with PE-DLBCL. The lack of CR was the only independent adverse prognostic factor for OS.
CONCLUSION
The clinical outcomes of patients with PE-DLBCL at our centre were encouraging, especially for patients with CNS and vitreoretinal involvement.
目的
分析中国原发性结外弥漫大 B 细胞淋巴瘤（PE-DLBCL）患者的临床特征和治疗反应。
方法
我们分析了 2015 年 1 月至 2020 年 12 月期间新诊断为 PE-DLBCL 的 197 例患者的临床特征和结局。
结果
胃肠道受累率最高（34%），其次是中枢神经系统（CNS）和眼内系统（31.5%）。全组患者 3 年总生存率（OS）为 81%，CNS 和玻璃体视网膜受累患者为 79%。Ann Arbor 分期、乳酸脱氢酶水平、国际预后指数（IPI）>2 和完全缓解（CR）与 PE-DLBCL 患者的生存显著相关。缺乏 CR 是 OS 的唯一独立不良预后因素。
结论
本中心 PE-DLBCL 患者的临床结局令人鼓舞，特别是 CNS 和玻璃体视网膜受累的患者。
Zotero 插件